These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 24925884)

  • 1. Correlation between in vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma.
    van Berkel A; Rao JU; Kusters B; Demir T; Visser E; Mensenkamp AR; van der Laak JA; Oosterwijk E; Lenders JW; Sweep FC; Wevers RA; Hermus AR; Langenhuijsen JF; Kunst DP; Pacak K; Gotthardt M; Timmers HJ
    J Nucl Med; 2014 Aug; 55(8):1253-9. PubMed ID: 24925884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic Subtyping of Pheochromocytoma and Paraganglioma by
    van Berkel A; Vriens D; Visser EP; Janssen MJR; Gotthardt M; Hermus ARMM; Geus-Oei LF; Timmers HJLM
    J Nucl Med; 2019 Jun; 60(6):745-751. PubMed ID: 30413658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
    van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
    J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superiority of
    Jha A; Ling A; Millo C; Gupta G; Viana B; Lin FI; Herscovitch P; Adams KT; Taïeb D; Metwalli AR; Linehan WM; Brofferio A; Stratakis CA; Kebebew E; Lodish M; Civelek AC; Pacak K
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):787-797. PubMed ID: 29204718
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Feral CC; Tissot FS; Tosello L; Fakhry N; Sebag F; Pacak K; Taïeb D
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):812-821. PubMed ID: 27900521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotype-Dependent Brown Adipose Tissue Activation in Patients With Pheochromocytoma and Paraganglioma.
    Puar T; van Berkel A; Gotthardt M; Havekes B; Hermus AR; Lenders JW; van Marken Lichtenbelt WD; Xu Y; Brans B; Timmers HJ
    J Clin Endocrinol Metab; 2016 Jan; 101(1):224-32. PubMed ID: 26574955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET.
    Rischke HC; Benz MR; Wild D; Mix M; Dumont RA; Campbell D; Seufert J; Wiech T; Rössler J; Weber WA; Neumann HP
    J Nucl Med; 2012 Sep; 53(9):1352-8. PubMed ID: 22836345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
    J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study.
    Blanchet EM; Taieb D; Millo C; Martucci V; Chen CC; Merino M; Herscovitch P; Pacak K
    J Nucl Med; 2015 Dec; 56(12):1849-54. PubMed ID: 26359261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
    Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature?
    Taïeb D; Sebag F; Barlier A; Tessonnier L; Palazzo FF; Morange I; Niccoli-Sire P; Fakhry N; De Micco C; Cammilleri S; Enjalbert A; Henry JF; Mundler O
    J Nucl Med; 2009 May; 50(5):711-7. PubMed ID: 19372492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
    Fischer A; Kloos S; Maccio U; Friemel J; Remde H; Fassnacht M; Pamporaki C; Eisenhofer G; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Zitzmann K; Bechmann N; Žygienė G; Richter S; Hantel C; Vetter D; Lehmann K; Mohr H; Pellegata NS; Ullrich M; Pietzsch J; Ziegler CG; Bornstein SR; Kroiss M; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
    J Clin Endocrinol Metab; 2023 Sep; 108(10):2676-2685. PubMed ID: 36946182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas.
    Mete O; Pakbaz S; Lerario AM; Giordano TJ; Asa SL
    Am J Surg Pathol; 2021 Sep; 45(9):1264-1273. PubMed ID: 33826547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [
    Noortman WA; Vriens D; de Geus-Oei LF; Slump CH; Aarntzen EH; van Berkel A; Timmers HJLM; van Velden FHP
    Eur Radiol; 2022 Oct; 32(10):7227-7236. PubMed ID: 36001126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of [
    Takenaka J; Watanabe S; Abe T; Hirata K; Uchiyama Y; Kimura R; Shinohara N; Kudo K
    Ann Nucl Med; 2023 Jan; 37(1):10-17. PubMed ID: 36301465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
    Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
    Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis.
    Zhao Z; Yoshida Y; Kurokawa T; Kiyono Y; Mori T; Okazawa H
    J Nucl Med; 2013 Apr; 54(4):499-506. PubMed ID: 23471314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
    Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic status determines
    Tiwari A; Shah N; Sarathi V; Malhotra G; Bakshi G; Prakash G; Khadilkar K; Pandit R; Lila A; Bandgar T
    J Med Imaging Radiat Oncol; 2017 Dec; 61(6):745-752. PubMed ID: 28585398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1α, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours.
    Toba H; Kondo K; Sadohara Y; Otsuka H; Morimoto M; Kajiura K; Nakagawa Y; Yoshida M; Kawakami Y; Takizawa H; Kenzaki K; Sakiyama S; Bando Y; Tangoku A
    Eur J Cardiothorac Surg; 2013 Aug; 44(2):e105-12. PubMed ID: 23674658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.